A "bulldozer" driven by anoxic bacteria for pancreatic cancer chemo-immunotherapy

被引:12
|
作者
Zhang, Huijuan [1 ,2 ,3 ,5 ]
Wang, Yaping [1 ]
Zhu, Ling [1 ,2 ]
Qi, Zijun [1 ]
Cao, Kexuan [1 ]
Chang, Junbiao [3 ,4 ,5 ]
Hou, Lin [1 ,2 ,5 ]
机构
[1] Zhengzhou Univ, Sch Pharmaceut Sci, Zhengzhou, Peoples R China
[2] Key Lab Targeting Therapy & Diag Crit Dis, Zhengzhou, Henan Province, Peoples R China
[3] Collaborat Innovat Ctr New Drug Res & Safety Evalu, Zhengzhou, Henan Province, Peoples R China
[4] Zhengzhou Univ, Sch Chem & Mol Engn, Zhengzhou, Peoples R China
[5] Zhengzhou Univ, Sch Pharmaceut Sci, 100, Kexue Rd, Zhengzhou 450001, Peoples R China
基金
中国国家自然科学基金;
关键词
PDAC; Tumor matrix barrier; ICD; Autophagy inhibition; Immunotherapy; IMMUNOGENIC CELL-DEATH;
D O I
10.1016/j.jconrel.2023.07.014
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Immune evasion is a major obstacle for pancreatic ductal adenocarcinoma (PDAC) therapy. Inhibition of autophagy can improve antigen presentation and enlarge immunogenic cell death (ICD) effect to generate a strong anti-tumor immune response. However, abundant extracellular matrix dominated by hyaluronic acid (HA) hinders the deep penetration of autophagy inhibitors and ICD inducers. Herein, an intelligent autophagy inhibitor hydroxychloroquine (HCQ) and chemotherapeutic drug doxorubicin (DOX) co-loaded "bulldozer" (HD@HH/EcN) driven by anoxic bacteria was constructed for PDAC chemo-immunotherapy. Results demonstrated that probiotic Escherichia coli 1917 (EcN) could carry hyaluronidases (HAases)-hybrided albumin nanoparticles (HD@HH) to reach PDAC tumor tissue quickly and accurately. Thereafter, HAases can efficiently cleave the tumor matrix barrier and promote HD@HH/EcN to accumulate at tumor hypoxic core significantly. After that, high level of glutathione (GSH) in tumor microenvironment (TME) induces intermolecular disulfide bond in HD@HH nanoparticles breakage, to precisely release HCQ and DOX. DOX can induce ICD effect. Meanwhile, HCQ can amplify DOX induced ICD effect by inhibiting tumor autophagy, which further increase cell surface expression of major histocompatibility complex class I (MHC-I) and augment recruitment of CD8+ T cell to improve immunosuppressive TME. This study provides a new strategy for PDAC chemo-immunotherapy.
引用
收藏
页码:660 / 671
页数:12
相关论文
共 50 条
  • [21] CHEMO-IMMUNOTHERAPY OF BRONCHOGENIC CARCINOMA
    SARNA, GP
    LOWITZ, BB
    HASKELL, CM
    CLINE, MJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 89 - 89
  • [22] Use of Stromal Intervention and Exogenous Neoantigen Vaccination to Boost Pancreatic Cancer Chemo-Immunotherapy by Nanocarriers
    Chattopadhyay, Saborni
    Liao, Yu-Pei
    Wang, Xiang
    Nel, Andre E.
    BIOENGINEERING-BASEL, 2023, 10 (10):
  • [23] Topical chemo-immunotherapy of melanoma
    Mizes, A.
    Carey, C. D.
    Friedman, B.
    Zhang, J.
    Korkmaz, E.
    Balmert, S.
    Erdos, G.
    Falo, L. D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S9 - S9
  • [24] CHEMO-IMMUNOTHERAPY OF CANINE LYMPHOSARCOMA
    CROW, SE
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 212 - 212
  • [25] Targeted chemo-immunotherapy of leukemia
    Khazaie, Khashayarsha
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1353 - 1354
  • [26] REQUIREMENTS FOR SUCCESSFUL IMMUNOTHERAPY AND CHEMO-IMMUNOTHERAPY OF A MURINE MODEL OF OVARIAN-CANCER
    VANHAELEN, CPJ
    FISHER, RI
    CANCER RESEARCH, 1981, 41 (03) : 980 - 983
  • [27] CHEMOTHERAPY VERSUS CHEMO-IMMUNOTHERAPY IN ADVANCED BREAST-CANCER
    MUSS, HB
    COOPER, MR
    RICHARDS, F
    WHITE, DR
    SPURR, CL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 356 - 356
  • [28] Intravesical chemo-immunotherapy in non muscle invasive bladder cancer
    Leopardo, D.
    Cecere, S. C.
    Di Napoli, M.
    Cavaliere, C.
    Pisano, C.
    Striano, S.
    Marra, L.
    Menna, L.
    Claudio, L.
    Perdona, S.
    Setola, S.
    Berretta, M.
    Franco, R.
    Tambaro, R.
    Pignata, S.
    Facchini, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2013, 17 (16) : 2145 - 2158
  • [29] Feasibility of combination chemo-immunotherapy (C-IT) in ovarian cancer
    Smith, L. Mary
    Schultes, Birgit C.
    Nicodemus, Christopher F.
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 872 - 873
  • [30] Biomarker-oriented chemo-immunotherapy for advanced gastric cancer
    Kono, Koji
    Nakajima, Shotaro
    Mimura, Kosaku
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (7) : 865 - 872